Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
Go back to Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease| (NASDAQ: AXSM) | Delayed: 247.82 -0.03 (0.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $247.85 | 52 Week High | $15.74 | |||
| Open | $247.85 | 52 Week Low | $5.37 | |||
| Day High | $252.03 | P/E | N/A | |||
| Day Low | $247.67 | EPS | $0.00 | |||
| Volume | 272,623 | |||||
